Summary:
A phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of Budesonide Foam (2MG/25ML BID for 2 weeks, followed by 2MG/25ML QD for 4 weeks)versus placebo in subjects with active mild to moderate ulcerative proctitis or proctosigmoiditis.
Qualified Participants Must:
• Be 18-75 years of age
•
Have diagnosis of active UP/UPS with mild to moderate symptoms
•
Be able to complete all 8 scheduled visits within approximately 11 weeks
Qualified Participants May Receive:
Study medication at no cost and reimbursement for time and travel may be provided.